Meeting
2020 ASCO Virtual Scientific Program
PD-L1 tumor proportion score and clinical benefit from first-line pembrolizumab in patients with advanced nonsquamous versus squamous non-small cell lung cancer (NSCLC).
Authors
Deborah Blythe Doroshow
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
Deborah Blythe Doroshow , Wei Wei , Jon Zugazagoitia , Charles Jack Robbins , Swati Gupta , Blythe J.S. Adamson , David L. Rimm
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9539)
DOI
10.1200/JCO.2020.38.15_suppl.9539
Abstract #
9539
Poster Bd #
305
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Sintilimab versus pembrolizumab in monotherapy or combination with chemotherapy as first-line therapy for advanced non–small cell lung cancer: Results from phase 2, randomized clinical trial (CTONG1901).
First Author: Si-Yang Maggie Liu
Poster
2020 ASCO Virtual Scientific Program
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small-cell lung cancer and a poor performance status.
First Author: Joao Victor Machado Alessi
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Outcomes of nivolumab (NIVO)-treated patients (pts) with advanced non-small cell lung cancer (aNSCLC) in United States community oncology practice.
First Author: Eric Nadler
Poster
2023 ASCO Annual Meeting
Phase 2 trial of epidermal growth factor (EGF) vaccine CIMAvax in combination with pembrolizumab in first line and maintenance setting in advanced non–small cell lung cancer patients.
First Author: Prantesh Jain